Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05YQL
|
||||
| Former ID |
DIB011681
|
||||
| Drug Name |
BM-ca
|
||||
| Synonyms |
Anti-CD20 antibodies (lymphoma), BioMedics
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Non-hodgkin's lymphoma [ICD10:C85] | Phase 1 | [1] | ||
| Company |
BioMedics Japan Inc
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | [2] | ||
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033790) | ||||
| REF 2 | BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties. Int J Oncol. 2011 Feb;38(2):335-44. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.